Abstract
613 Background: We are conducting a Phase II clinical trial of the HER2 peptide vaccine AE37 (MHC Class II binding) for the prevention of breast cancer recurrence in disease-free, node-positive or ...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
